Search results for: Eli Lilly
Filter search results
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
…used a promising technique for addressing uncertainty called expert elicitation. Expert elicitation provides a framework in which people ‘in the know’ can provide estimates for unknown quantities and estimate their…
Franz Pichler
10 April 2026
…years in the Global Public Policy team at Eli Lilly, working in Europe, Japan and China. He is also a senior research fellow at the School of Pharmacy, University of…
“New Age” Decision Making in HTA: Is It Applicable in Asia?
1 August 2016
…annual meeting in Tokyo. The panel session was entitled “New Age Decision Making in HTA: Is It Applicable in Asia?”. To open the session, David Grainger (Eli Lilly & Company)…
How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
8 January 2016
…“How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?” and was chaired by Franz Pichler (Eli Lilly & Company)….
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…wellbeing measures. The panel was sponsored by Eli Lilly. Presentation by Paula Lorgelly – Beyond QALYs: A Quantum Leap Forward or a Leap in the Dark? from Office of Health…
Recently published: Are Wider Societal Effects Considered in Healthcare Decision-making?
29 February 2016
…based on a research study that was funded by Eli Lilly and Company. Download the full paper here. Full reference: Garau, M., Shah, K.K., Sharma, P. and Towse, A., 2016….
OHE at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad
19 June 2015
…research. OHE presentations are summarised below. New Clinical Development Paradigm for Drugs Sean Tunis (Center for Medical Technology Policy: CMTP), Adrian Towse (OHE), Sarah Garner (NICE) Franz Pichler (Eli Lilly)….
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
…in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis[1]. A…
A New Valuation Method: Directly Eliciting Personal Utility Functions
30 August 2017
A new OHE Research Paper describes a novel approach for valuing health-related quality of life: directly eliciting personal utility functions Methods commonly used for eliciting the preference data upon which…